2seventy bio, Inc.
TSVT
$4.99
$0.010.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -62.28% | -68.73% | -70.04% | -42.90% | 9.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -62.28% | -68.73% | -70.04% | -42.90% | 9.72% |
| Cost of Revenue | -59.83% | -47.14% | -32.32% | -17.92% | -9.92% |
| Gross Profit | 58.17% | 19.04% | -15.34% | -3.16% | 19.72% |
| SG&A Expenses | -36.72% | -28.25% | -34.13% | -19.60% | -12.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.77% | -43.02% | -32.74% | -18.29% | -10.53% |
| Operating Income | 51.30% | 22.64% | 4.57% | 4.59% | 17.57% |
| Income Before Tax | 73.69% | 48.58% | 13.26% | -3.60% | 14.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.69% | 48.58% | 13.26% | -3.60% | 14.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.69% | 48.58% | 13.26% | -3.60% | 14.39% |
| EBIT | 51.30% | 22.64% | 4.57% | 4.59% | 17.57% |
| EBITDA | 52.31% | 23.25% | 5.00% | 4.76% | 17.88% |
| EPS Basic | 75.12% | 53.12% | 28.72% | 20.41% | 41.77% |
| Normalized Basic EPS | 56.76% | 29.46% | 22.99% | 30.44% | 47.12% |
| EPS Diluted | 74.54% | 52.49% | 28.16% | 20.33% | 41.72% |
| Normalized Diluted EPS | 57.16% | 29.92% | 23.36% | 30.44% | 47.12% |
| Average Basic Shares Outstanding | 6.02% | 12.81% | 20.46% | 29.23% | 38.36% |
| Average Diluted Shares Outstanding | 7.45% | 14.34% | 22.11% | 29.23% | 38.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |